Emergent Biosolutions Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $4.04
- Today's High:
- $4.26
- Open Price:
- $4.19
- 52W Low:
- $7.74
- 52W High:
- $36.14
- Prev. Close:
- $4.22
- Volume:
- 1969755
Company Statistics
- Market Cap.:
- $399.04 million
- Book Value:
- 23.861
- Revenue TTM:
- $978.50 million
- Operating Margin TTM:
- -32.18%
- Gross Profit TTM:
- $236.80 million
- Profit Margin:
- -41.2%
- Return on Assets TTM:
- -6.87%
- Return on Equity TTM:
- -29.02%
Company Profile
Emergent Biosolutions Inc had its IPO on 2006-11-15 under the ticker symbol EBS.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Emergent Biosolutions Inc has a staff strength of 2,500 employees.
Stock update
Shares of Emergent Biosolutions Inc opened at $4.19 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4.04 - $4.26, and closed at $4.11.
This is a -2.61% slip from the previous day's closing price.
A total volume of 1,969,755 shares were traded at the close of the day’s session.
In the last one week, shares of Emergent Biosolutions Inc have slipped by -19.09%.
Emergent Biosolutions Inc's Key Ratios
Emergent Biosolutions Inc has a market cap of $399.04 million, indicating a price to book ratio of 0.41 and a price to sales ratio of 0.3672.
In the last 12-months Emergent Biosolutions Inc’s revenue was $978.50 million with a gross profit of $236.80 million and an EBITDA of $-173200000. The EBITDA ratio measures Emergent Biosolutions Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Emergent Biosolutions Inc’s operating margin was -32.18% while its return on assets stood at -6.87% with a return of equity of -29.02%.
In Q1, Emergent Biosolutions Inc’s quarterly earnings growth was a positive 2.2% while revenue growth was a negative 46.3%.
Emergent Biosolutions Inc’s PE and PEG Ratio
- Forward PE
- 7.9428
- Trailing PE
- 0
- PEG
- 1.55
Its diluted EPS in the last 12-months stands at $-7.78 per share while it has a forward price to earnings multiple of 7.9428 and a PEG multiple of 1.55. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Emergent Biosolutions Inc’s profitability.
Emergent Biosolutions Inc stock is trading at a EV to sales ratio of 0.9294 and a EV to EBITDA ratio of 4.8941. Its price to sales ratio in the trailing 12-months stood at 0.3672.
Emergent Biosolutions Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $2.95 billion
- Total Liabilities
- $1.22 billion
- Operating Cash Flow
- $-15100000.00
- Capital Expenditure
- $15.10 million
- Dividend Payout Ratio
- 0%
Emergent Biosolutions Inc ended 2024 with $2.95 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.95 billion while shareholder equity stood at $1.20 billion.
Emergent Biosolutions Inc ended 2024 with $59.70 million in deferred long-term liabilities, $1.22 billion in other current liabilities, 100000.00 in common stock, $551.00 million in retained earnings and $218.20 million in goodwill. Its cash balance stood at $430.20 million and cash and short-term investments were $430.20 million. The company’s total short-term debt was $950,700,000 while long-term debt stood at $447.70 million.
Emergent Biosolutions Inc’s total current assets stands at $1.22 billion while long-term investments were $0 and short-term investments were $0. Its net receivables were $155.90 million compared to accounts payable of $124.20 million and inventory worth $367.90 million.
In 2024, Emergent Biosolutions Inc's operating cash flow was $-15100000.00 while its capital expenditure stood at $15.10 million.
Comparatively, Emergent Biosolutions Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $4.11
- 52-Week High
- $36.14
- 52-Week Low
- $7.74
- Analyst Target Price
- $17.75
Emergent Biosolutions Inc stock is currently trading at $4.11 per share. It touched a 52-week high of $36.14 and a 52-week low of $36.14. Analysts tracking the stock have a 12-month average target price of $17.75.
Its 50-day moving average was $6.06 and 200-day moving average was $9.66 The short ratio stood at 4.53 indicating a short percent outstanding of 0%.
Around 76% of the company’s stock are held by insiders while 9552.4% are held by institutions.
Frequently Asked Questions About Emergent Biosolutions Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care. The company offers ACAM2000, a smallpox vaccine; Anthrasil to for inhalational anthrax; Botulism Antitoxin Heptavalent to treat botulinum disease; BioThrax, an anthrax vaccine; Ebanga, a monoclonal antibody to treat infection caused by Zaire ebolavirus; raxibacumab injection for the treatment of inhalational anthrax; reactive skin decontamination lotion kits; TEMBEXA for the treatment of human smallpox disease; Trobigard, an auto-injector atropine sulfate and obidoxime chloride auto-injector for the emergency treatment of known or suspected exposure to nerve agents; and vaccinia immune globulin intravenous that addresses complications from smallpox vaccine. It also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, the company is developing AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; EBS-LASV; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.